Global to push GA events into
skip to main content

Title: Uses of monoclonal antibody 8H9

This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof.
Inventors:
Issue Date:
OSTI Identifier:
1434705
Assignee:
Sloan-Kettering Institute for Cancer Research (New York, NY) CHO
Patent Number(s):
9,938,351
Application Number:
15/365,803
Contract Number:
FG02-93ER61658
Resource Relation:
Patent File Date: 2016 Nov 30
Research Org:
Sloan-Kettering Institute for Cancer Research, New York, NY (United States)
Sponsoring Org:
USDOE
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES